<?xml version='1.0' encoding='utf-8'?>
<document id="26303765"><sentence text="Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings." /><sentence text="Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials" /><sentence text=" One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities" /><sentence text=" This is in contrast to the clinical setting in which new medications are added to the &quot;standard of care&quot; treatment that by now includes a growing number of medications" /><sentence text=" Drug-drug interaction may lead to alteration, dampening, augmenting or masking the effects of the intended intervention" /><sentence text=" We use the well described model of statin-induced myocardial protection to demonstrate potential interactions with agents which are commonly concomitantly used in patients with stable coronary artery disease and/or acute coronary syndromes" /><sentence text=" These interactions could potentially explain the reduced efficacy of statins in the clinical trials compared to the animal models" /><sentence text=" In particular, caffeine and aspirin could attenuate the infarct size limiting effects of statins; morphine could delay the onset of protection or mask the protective effect in patients with ST elevation myocardial infarction, whereas other anti-platelet agents (dipyridamole, cilostazol and ticagrelor) may augment (or mask) the effect due to their favorable effects on adenosine cell reuptake and intracellular cAMP levels"><entity charOffset="16-24" id="DDI-PubMed.26303765.s8.e0" text="caffeine" /><entity charOffset="29-36" id="DDI-PubMed.26303765.s8.e1" text="aspirin" /><entity charOffset="99-107" id="DDI-PubMed.26303765.s8.e2" text="morphine" /><entity charOffset="263-275" id="DDI-PubMed.26303765.s8.e3" text="dipyridamole" /><entity charOffset="277-287" id="DDI-PubMed.26303765.s8.e4" text="cilostazol" /><entity charOffset="292-302" id="DDI-PubMed.26303765.s8.e5" text="ticagrelor" /><entity charOffset="371-380" id="DDI-PubMed.26303765.s8.e6" text="adenosine" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e0" e2="DDI-PubMed.26303765.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e1" e2="DDI-PubMed.26303765.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e1" e2="DDI-PubMed.26303765.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e1" e2="DDI-PubMed.26303765.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e1" e2="DDI-PubMed.26303765.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e1" e2="DDI-PubMed.26303765.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e1" e2="DDI-PubMed.26303765.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e2" e2="DDI-PubMed.26303765.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e2" e2="DDI-PubMed.26303765.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e2" e2="DDI-PubMed.26303765.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e2" e2="DDI-PubMed.26303765.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e2" e2="DDI-PubMed.26303765.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e3" e2="DDI-PubMed.26303765.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e3" e2="DDI-PubMed.26303765.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e3" e2="DDI-PubMed.26303765.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e3" e2="DDI-PubMed.26303765.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e4" e2="DDI-PubMed.26303765.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e4" e2="DDI-PubMed.26303765.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e4" e2="DDI-PubMed.26303765.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e5" e2="DDI-PubMed.26303765.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26303765.s8.e5" e2="DDI-PubMed.26303765.s8.e6" /></sentence><sentence text=" We recommend that after characterizing the effects of new modalities in single intervention bench research, studies should be repeated in the background of standard-of-care medications to assure that the magnitude of the effect is not altered before proceeding with clinical trials" /><sentence text=" " /></document>